Remarks

Claims 1 and 2 are under consideration and stand rejected under the judicially created doctrine of obviousness-type double patenting as unpatentable over claims 9, 10 and 12 of U.S. Patent No. 6,675,070.

To obviate the foregoing rejection a Terminal Disclaimer is submitted herewith together with the terminal disclaimer fee under 37 C.F.R. 1.20(d) of \$65.00. Please charge any additional fees concerning this matter or credit any overpayment to Deposit Account No. 15-0508.

This application is now deemed to be in condition for allowance. Early such action is solicited.

Respectfully submitted,

Talivaldis Cepuritis (R/gg. No. 20,818)

March 30, 2005

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606 (312) 580-1180